Celcuity (NASDAQ:CELC) Coverage Initiated by Analysts at Citizens Jmp

Citizens Jmp began coverage on shares of Celcuity (NASDAQ:CELC) in a report published on Monday morning, Marketbeat.com reports. The brokerage issued a market outperform rating and a $150.00 price target on the stock.

Other analysts have also recently issued reports about the stock. Wall Street Zen cut shares of Celcuity from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Celcuity in a research note on Monday, April 20th. Citigroup assumed coverage on shares of Celcuity in a research note on Monday. They set an “outperform” rating for the company. Needham & Company LLC reissued a “buy” rating and set a $122.00 price objective on shares of Celcuity in a research note on Thursday, March 26th. Finally, Wolfe Research reissued an “outperform” rating and set a $110.00 price objective on shares of Celcuity in a research note on Thursday, March 12th. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $114.33.

Celcuity Trading Up 3.8%

Shares of Celcuity stock opened at $125.68 on Monday. Celcuity has a fifty-two week low of $9.51 and a fifty-two week high of $129.09. The business’s fifty day moving average is $113.72 and its two-hundred day moving average is $101.08. The firm has a market cap of $6.08 billion, a PE ratio of -33.16 and a beta of 0.41. The company has a quick ratio of 10.55, a current ratio of 10.55 and a debt-to-equity ratio of 3.20.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings data on Wednesday, March 25th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $0.09. Analysts anticipate that Celcuity will post -3.97 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Richard E. Buller sold 3,000 shares of the company’s stock in a transaction on Tuesday, March 31st. The shares were sold at an average price of $110.27, for a total transaction of $330,810.00. Following the completion of the sale, the director directly owned 6,760 shares of the company’s stock, valued at approximately $745,425.20. This represents a 30.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 13.33% of the company’s stock.

Institutional Trading of Celcuity

A number of institutional investors have recently added to or reduced their stakes in CELC. Avoro Capital Advisors LLC purchased a new stake in Celcuity during the 4th quarter worth $310,302,000. NEA Management Company LLC boosted its position in Celcuity by 64.9% during the 4th quarter. NEA Management Company LLC now owns 3,535,561 shares of the company’s stock worth $352,637,000 after purchasing an additional 1,391,300 shares during the period. State Street Corp boosted its position in Celcuity by 126.6% during the 4th quarter. State Street Corp now owns 1,637,687 shares of the company’s stock worth $163,343,000 after purchasing an additional 914,887 shares during the period. Apis Capital Advisors LLC purchased a new stake in Celcuity during the 3rd quarter worth $38,334,000. Finally, UBS Group AG boosted its position in Celcuity by 910.1% during the 3rd quarter. UBS Group AG now owns 854,483 shares of the company’s stock worth $42,211,000 after purchasing an additional 769,891 shares during the period. 63.33% of the stock is owned by hedge funds and other institutional investors.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.